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ABSTRACT 
 
Murine typhus is a disease (brought on by infection with Rickettsia typhi) that 
has produced a surprising amount of morbidity when the relative dearth of literature on 
the subject is considered.  Existing reviews of the subject are either relatively dated or 
surveys of all rickettsial disease with the majority of discussion dedicated to other 
agents, most often Rickettsia prowazekii or Rickettsia felis.  This is likely due to the 
widespread consideration that Murine typhus is a “re-emergent organism” that was 
largely removed by the use of pesticides in the 1950s and has only recently re-emerged 
in much of the globe.  I utilize a review of several databases to assess the literature 
regarding Murine typhus and to bring together summary information for a multitude of 
factors about the disease. 
I found a remarkable heterogeneity of data regarding Murine typhus.  Factors of 
specific note among the cases reviewed include the relatively high amount of probable 
exposures reported by patients, the difficulty at reaching the proper diagnosis 
experienced by physicians when attempting to ascertain the cause of symptoms, the 
many separate treatments used and differential efficacies of those treatments, and the 
disparate types of “severe” outcomes.  This information may be of use in the coming 
years as Murine typhus continues to increase in incidence in many nations where it is 
present, and as it also appears in those nations where it has not been seen in the previous 
50 years.     
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CHAPTER I 
INTRODUCTION, METHODS, AND RESULTS 
Murine typhus is a condition stemming from Rickettsia typhi (formerly Rickettsia 
mooseri) infection.  This disease has been claimed to be “forgotten” or, alternatively, 
“re-emergent.”  While it is true that there was a sharp reduction in Murine typhus cases 
in most nations that used the pesticide DDT (dichlorodiphenyltrichloroethane) in the 
1940s and 50s, this change was not necessarily a worldwide trend.  Recently, an increase 
in interest in Murine typhus in scholastic research has corresponded with the increasing 
reports of the disease from many of those areas of the globe that had once been dubbed 
“typhus-free.”  The purpose of this study is to analyze newly available information and 
present summary statistics regarding recent trends in Murine typhus-related topics 
ranging from symptom presentation to treatment efficacy to the specific threats this 
resurgence poses to certain regions.  A comprehensive, systematic review design was 
selected to accomplish this aim.  The study presented here represents the first attempt the 
author has been able to find that analyzes Murine typhus cases over a long time period 
(from 1972-2014, 32 years).  A previous study of nine years was located, as well as a 
summary representing seven years.  This examination will also represent one of the 
larger non-serologic examinations of Murine typhus cases conducted, although no direct 
interventions are conducted. Previous studies have frequently been in response to 
outbreaks1,2  or are reports of a single patient/manifestation/treatment of interest of the 
disease, and have been limited to either a single country or geographic region as well.  
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One advantage found in the multi-national plan detailed here is that I hope to eliminate 
national biases by bringing in data from multiple nations in several regions, another first 
as far as Murine typhus studies are considered.  While there have been a number of large 
seroprevalence studies, I hope to provide some information (via summary statistics) on 
the way Murine typhus is studied, on the progression of the disease, on the way the 
disease is diagnosed and the effects an expeditious diagnosis has on the disease, and on 
the temporal-spatial trends of the disease over the previous 32 years.       
 
I.1 METHODS   
I conducted a systematic review of literature pertaining to Murine typhus by 
searching the MEDLINE, EMBASE, Global Health, and the Northern Light Life 
Sciences Conference Abstracts databases for articles.  An external filter was applied to 
select only those studies that had occurred post-1972.  After retrieval, each article was 
reviewed by two reviewers – one reviewer who reviewed every article to provide 
consistency and one reviewer who only analyzed 78 articles (Figure 1.1).  These 
reviews were then compared with each other to determine inclusion or exclusion of a 
study.  In those cases where a discrepancy occurred, both reviewers conferred with an 
additional reviewer and made a decision regarding the inclusion (or lack thereof) for the 
article.  The following set of criteria was used when determining whether to exclude the 
article or not: Was the article in English? Was the article detailing Murine typhus 
infections? Did the article describe infections of humans?  Geographic data were 
harvested from articles that met these criteria.  A “second phase” of analysis occurred 
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afterwards in which each article was examined thoroughly to determine whether it was 
suitable for use in the building of summary statistics for the disease.  The only criteria 
used for this step was the presence or absence of descriptions of the clinical 
characteristics of the case.  While this step of abstraction used a slightly ambiguous 
definition, this kind of flexibility was necessary to ensure that larges studies that did not 
have information suitable for the development of summary statistics (for example, a 
seroprevalence study) would be excluded as necessary.   
 
 
Figure 1.1: Graphical Representation of Reviewer Workload by Reviewer 
Number and Article Reference 
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I.1.1 Development of Phase 1 Data 
“Phase 1” data refers to that data gathered using the aforementioned search and 
exclusion criteria with the exception of the “study design” criteria.  This data was 
intended to provide a representation of regions where human Murine typhus is either 
being actively researched or reported in scholarly journals.  Ten regions were selected 
for aggregated Murine typhus reporting:  North America, Central America, South 
America, North Africa, Saharan and Sub-Saharan Africa, the Middle East, Europe, India, 
Asia, and Australia.  These regions were selected based on pre-existing geographic 
convention.  Additionally, data on year published was gathered and recorded.  Multiple 
reviewers were used to select these articles, and corresponding inter-rater reliability 
(utilizing the Cohen’s Kappa statistic3 and Landis and Koch’s criteria for assessment4) 
was calculated.     
 
I.1.2 Development of Phase 2 Data 
“Phase 2” data refers to that data gathered from the Phase 1 data with the 
additional exclusion factor of study design.  Because this review was designed to 
compare certain summary statistics (described in detail later in this section), large scale 
seroprevalence studies were excluded, as they do not typically enter into sufficient depth 
of analysis of cases to provide the necessary statistics.  As a result, studies that did not 
detail the clinical course of the disease in humans were excluded from Phase 2 
(generation of summary statistics) analysis.  Once articles were selected for Phase 2, the 
following data was acquired from said articles if presented: patient age, gender, 
 5 
 
race/ethnicity, suspected exposure, total days from onset to end of symptoms, total 
symptomatic days (this number differs from total days from onset to end in cases with a 
relapse as mentioned in background), initial diagnosis, subsequent diagnoses, reported 
prior health history, initial treatments, final treatment, time from final treatment to 
resolution of symptoms (measured by release from hospital or first afebrile/otherwise 
asymptomatic day, whichever occurs first), oral fever temperature (in Celsius) at 
admission, maximum fever temperature (oral only, in Celsius), presence and type of 
rash, presence of headache during course of disease, additional symptoms (this box was 
kept free to accommodate as much freedom to record novel results as possible), and 
continuing symptoms (a measure of long term debilitation suffered by Murine typhus 
infection).  If data could not be acquired for a minimum of eight of the 16 fields (the 
final two fields, additional and continuing symptoms, were not considered for inclusion 
criteria and were only included to facilitate a comprehensive analysis of unforeseen 
factors), the case was discarded for lack of information.   
 
I.2 RESULTS   
The search retrieved 312 unique articles (the data storage system automatically 
eliminated duplicated names, although there were four cases of articles with similar, 
although different names that otherwise described the exact same cases and were 
subsequently excluded).  Sixty-one articles could not be recovered in a full-text format 
and were excluded from the study along with one copy each of the duplicated articles 
(for a total of 63 discarded).   Fifty-one articles were excluded from analysis due to an 
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agent of interest other than Murine typhus.  Twelve articles were excluded from analysis 
due to a focus on non-human populations.  Nineteen articles could not be recovered in 
English.  Sixty-nine articles were excluded from Phase 2 analysis for not reporting 
clinical information that would support the development of summary statistics but 
remained in Phase 1.  Ninety-eight articles remained at the end of the exclusion phase.  
Of these, 40 articles were excluded due to lack of information of interest, and a single 
case was excluded as a laboratory exposure (the author did not feel this study was likely 
to represent an accurate portrayal of the course of the disease).  Fifty-seven articles were 
used in the creation of summary statistics.  Because Murine typhus articles sometimes 
include summaries of multiple cases, these 57 articles presented comprehensive 
information on 68 cases, an average of 1.17 cases per article.  This search is described in 
an image in Figure 1.2.         
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Figure 1.2:  Flowchart Describing Results of Selection Criteria
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Analysis of inter-rater reliability was performed between reviewer one (who 
reviewed every article) and the other reviewers.  This analysis was conducted using the 
inclusion/exclusion criteria for the Phase 1 statistics described previously (i.e., 
agreement between the two raters on the language of a document, whether or not the 
document assessed humans, whether the study design supported further analysis in Phase 
2, and whether or not the document assessed Murine typhus).  Cohen’s Kappa method 
was used to assess agreement between the reviewers.3 The subjective method of 
assessing results based on the paper by Landis and Koch was selected to assess IRR.4 
The results of the individual analyses can be found in Table 1.1.  All Kappa scores fall 
well within the margin for “substantial” or “almost perfect” agreement, indicating a 
generally positive result for inter-rater agreement. 
 
 
Table 1.1: Inter-Rater Reliability 
Rater 1st rater:1 1st rater:1 1st rater:1 1st rater:1 
Rater 2nd rater:2 2nd rater:3 2nd rater:4 2nd rater:5 
Cohen’s Kappa .782 .611 .640 .828 
Agreement 
Assessment by 
Landis and Koch4 
“Substantial” “Substantial” “Substantial” “Almost 
perfect” 
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I.2.1 Phase 1 Results 
The regional results for the 167 articles selected for Phase one results are 
presented in Figure 1.3.  The most common regions were Asia (46), Europe (31), and 
North America (26).  Four articles were examinations of data comprised of two or more 
regions, and are reported as “did not identify.” 
 
 
 
Figure 1.3:  Number of Articles by Region 
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Additionally, data on individual nation of origin was also acquired, and the 
nations that provide the primary source of Murine typhus articles are presented in Figure 
1.4.  Specific states of the United States are presented in independent columns due to 
variances in reporting.  Only the most common reporting nations are presented in Figure 
1.4. 
 
 
Figure 1.4:  Number of Articles by 
Nation 
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In terms of temporality, there has been an upward trend in Murine typhus 
publications yearly (with slight variances).  This matches the upward trend in all medical 
literature observed over the study time of interest.  After Winsorizing of top and bottom 
2%, an approximately 300% increase since the beginning of the analyzed period was 
observed.  This increase represented only 42% of the increase in total papers published 
in the corresponding databases.  It is unknown as to why the increase was so much lower 
than might have been expected, but it may have to do with the relatively unknown nature 
of the condition.   
 
I.2.2 Phase 2 Results 
 It is important to note that, at this phase of the study, reporting figures have 
shifted from the previously reported “articles” to the new figure “cases.”  This is due to 
the presence of multiple cases inside some articles.  A single article may cover the 
course of disease, treatment, and recovery for two or more people.  Indeed, one article 
has four well described cases and was included in all the statistics presented throughout 
this document.  In an effort to most accurately report trends and to acquire as much data 
as possible, all cases with sufficient clinical data (at least eight/16 abstraction fields 
could be gathered) will be reported.  Sixty-eight unique cases were selected for analysis 
based on the presence of sufficient data after abstraction.  There was an average of 1.17 
cases per report analyzed, as most Murine typhus reports contain only a single case.  
Race/ethnicity was only reported in 21% of cases, and so was excluded from later 
analyses.  Similarly, subsequent incorrect diagnoses were reported for approximately 
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19% of cases, and thus were excluded from computation of summary statistics.  Long 
term symptoms were relatively rare, but were considered an important clinical descriptor 
and were retained for description although no analysis of this variable was conducted.   
 Determining the characteristics of the population afflicted with Murine typhus is 
an important aspect of this project. The ages reported ranged from three – 81, with a 
mean of 38.42.  The distribution of ages was approximately normal about the mean with 
a slight left skew.  These factors were compared across region, but due to the relatively 
small sample size, it was difficult to determine specific regional trends.  Fever at 
admission is notable in its constancy – while patients individually reached higher or 
lower temperatures, the means for regions remained remarkably similar.  For example, 
North America had a 39.05 mean, Europe a 39.038, Australia a 39.07, and Asia a 
39.069.  Maximum fever temperature also was similar throughout the globe.    
Further analysis of exposures reported is presented in Table 1.2.  When multiple 
animal exposures were reported, each exposure was recorded and analyzed separately.  
Only animal exposures with supporting information in prior literature were included 
(there were three cases reporting injuries while swimming, three reporting contact with 
garbage or “unclean parts of the city”, two reporting ill family members, one reporting 
mosquito bites.  As none of these are supported by prior reports or by etiologic 
reasoning, and the reports are few in number, only those animal exposures that have 
been proposed as reservoirs/vectors for Murine typhus are reported formally).  There 
was one interesting relationship discovered in this section – eight/12 (66%) of patients 
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who reported exposure to rats and mice were from North America.  This represented 
50% of all patients from North America who reported exposures.    
 
 
 
Table 1.2: Exposures by Animal Type and Number 
Reported 
Animal exposure Reported exposures 
Rats and Mice 12  
Cats 9 
Insects (Fleas and Ticks and bites of the two 
organisms) 
7 
Dogs 3 
Opossums 2 
Cattle 2 
Exotic  1 
Goats 1 
Sheep 1 
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Data regarding diagnoses were readily available for most articles.  Table 1.3 
reports the different diagnoses reported for these patients. 
 
 
Table 1.3: Initial Diagnoses of Murine typhus Cases 
Initial Diagnosis Number 
Viral Illness 8 
Murine typhus 4 
Upper respiratory infection 3 
Dengue Fever 2 
Influenza 2 
Rickettsial disease 2 
Bacterial Endocarditis 1 
Bacterial illness 1 
Kawasaki syndrome 1 
Malaria or Salmonellosis 1 
Mononucleosis 1 
Pharyngitis 1 
Pneumonia 1 
Scrub typhus 1 
Typhoid Fever 1 
Enteric Fever 1 
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The most common initial diagnosis made is that of “viral illness/disease.”  This 
diagnosis is made 12% of the time.  The accurate diagnosis was made in only 6% of 
reported cases, while a diagnosis of “rickettsial disease,” which is technically accurate 
though perhaps less-than-useful, was made 3% of the time.  Scrub typhus is also a very 
similar disease (Orientia tsutsugamushi, the causative agent, has been considered a 
member of the rickettsial diseases).6  Dengue fever, Influenza, and upper respiratory 
tract infection are also common false diagnoses.  The “proper diagnosis” was made only 
in California, China (PRC), and Brazil.  None of these nations (or states) are considered 
true hotbeds of Murine typhus activity, although each have seen an increase in Murine 
typhus reports in the past 20 years.  None of the cases correctly diagnosed were 
prescribed the same course of treatment.  All cases initially diagnosed correctly were 
eventually administered Doxycycline and made full recoveries.  There were no other 
important similarities between the cases properly diagnosed, with the exception that each 
had a rash.  There were no meaningful correlations relating to diagnosis by region; with 
such small sample sizes, evaluation of such trends becomes difficult.        
 Little information was provided in the reports regarding pre-existing health 
outcomes, however, one important fact should be noted here that 6% of cases were 
pregnant at the time they were examined.  This author completed an extensive review of 
literature and could find no proposed reason, nor could I determine any theoretical 
reason, for this consistency of reports of pregnancy.  While it is known that certain insect 
species do attack pregnant women at a higher rate, I did not find any report of such an 
increase among Xenopsylla cheopis or Ctenocephalides felis, the primary vectors for the 
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disease.5  It is also possible that there is a “publication bias” that would have caused a 
selection effect but that may be unlikely when it is considered that single cases of murine 
typhus seem to be unique enough to be published without a corresponding health effect.  
Additionally, the increased surveillance of pregnancy was considered, but not a single 
case was diagnosed at a regularly scheduled medical examination – all cases reported 
after at least two days of fever.  The majority of pregnant cases were located in Europe.  
While this effect does not likely represent a meaningful trend, the importance of this 
special population compels me to mention it as an avenue for potential future study.    
 Treatments commonly prescribed for Murine typhus are mentioned below.  
Initial treatments were noted and reported for all patients (Table 1.4).  Doxycycline (a 
tetracycline drug) was most common, followed by Amoxicillin and Ceftriazone.  Only 
half of the Doxycycline patients were suspected of rickettsial disease, Scrub typhus, or 
Murine typhus.  Amoxicillin is a common broad-spectrum antibiotic that is frequently 
prescribed in cases of known or suspected bacterial illness.    
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Table 1.4: Initial Treatment 
Initial treatment Percent of treatments 
Amoxicillin 19.6% 
Ampicillin 5.6% 
Azithomycin 5.6% 
Ceftriaxone 16.8% 
Clarithomycin 2.8% 
Acyclovir 2.8% 
Methanesulfonamide 2.8% 
Clavulanic Acid 5.6% 
Doxycycline 28% 
Erythomycin 2.8% 
Minocycline 2.8% 
Natural recovery 2.8% 
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Final treatments for patients were recorded and reported in Table 1.5.  
Doxycycline alone was most common (42%), followed by Doxycycline in conjunction 
with any other drug or combination of drugs, then non-specific tetracylines alone.  
Tetracyclines are a family of drugs that include Doxycycline and are widely considered 
the gold standard for Murine typhus treatment.  Chloramphenicol, an often mentioned 
treatment for Murine typhus, was present as well.  A mix of other drugs and natural 
recovery (two cases reported recovery and specifically mention no use of other 
treatments) made up the remaining 21%.     
 
 
 
Table 1.5:  List of Final Treatments 
Final treatment Number treated 
Doxycycline alone 28 (42%) 
Doxycycline with other drugs 13 (19%) 
Non-Doxycycline tetracyclines alone 8 (12%) 
Chloramphenicol 4 (6%) 
   
 
 
 The only other result of interest in this study was regarding rash presence or lack 
thereof.  The prevalence of rash at any point in the illness was found to be 68%, a 
relatively high number, although within the bounds of previous studies.  This is likely 
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due to the diagnostic value of a rash in Murine typhus diagnosis causing cases to be 
selected. More information is needed to properly assess this variable. 
 The following chapters present an analysis of the data acquired in the systematic 
literature search and attempt to fully review Murine typhus.     
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CHAPTER II 
 A REVIEW OF MURINE TYPHUS 
 
Murine typhus (the disease caused by Rickettsia typhi) infection is caused when 
the Gram negative obligate intracellular bacterium enters a human body after 
transmission from an insect vector.6  This bacterium is a member of the family that also 
includes the causal agents for epidemic typhus (Rickettsia prowazekii), Mediterranean 
spotted fever (Rickettsia conorii), and Rocky Mountain spotted fever (Rickettsia 
ricketsii).6 Murine typhus begins to cause symptoms after the disease enters the 
bloodstream, where it infects endothelial cells.  In some cases, the disease has been 
known to spread to organs and can cause numerous medical problems as described 
below.  Patients frequently present with a fever and headache, and occasionally with a 
rash.  Left untreated, the disease can cause organ failure and even death, although this 
outcome is usually seen in elderly patients only.   
Murine typhus spreads using a relatively classic reservoir-vector-human victim 
cycle, with various warm blooded animals standing in as reservoirs and several insect 
species serving as vectors.  Indeed, the name (Murine) is purposefully reminiscent of 
Muridae, the Latin name for the largest family of rodents.  It is then appropriate that the 
Forest rat (Rattus rattus) and the Norwegian rat (Rattus norvegicus) are commonly 
named as vectors, although other animals have been shown to play a role as reservoirs as 
well.7,8  Along with other rodents (the common striped field mouse Apodemus agrarius 
and Crocidura lasiura),9,10 the common Opossum(Didelphus Marsupialis)11 has been 
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shown to serve as a reservoir in some cases, and animals as varied as dogs,12 cats,13 goats 
and cattle,14 and even sheep15 have been shown to be serologically positive potential 
sources of Murine typhus as well.  It is of note that at least one study found that presence 
of domestic dogs and cats in a house did not increase risks to attain Murine typhus, and 
the role of these organisms in the transmission of the disease is a matter of at least some 
debate.16  Some evidence exists to suggest exotics to include the elephant, orangutan, 
and lion may be reservoir candidates as well, although empirical research into the role of 
such creatures in Murine typhus transmission is lacking.17  As new hosts are continuing 
to be added to the list of “original suspects” (the rodent species), there is little doubt that 
the above list of reservoirs will continue to increase.  
While these reservoirs are an important piece of the Murine typhus puzzle, the 
disease cycle is not fully understood until the arthropod vectors are taken into 
consideration.  For much of history, the rat flea (Xenopsylla cheopis) was held to be the 
primary vector of Murine typhus.18  This flea has shown the ability (in lab settings) to 
transfer the infection within seven days after taking a meal from an infected rat, although 
evidence exists to show that the disease transmission is modulated by temperature.19  In 
recent years, an increasing number of studies have found that the cat flea 
(Ctenocephalides felis), often in conjunction with the opossum, also plays a role in the 
spread of the disease.20,21  Another flea species,  Leptopsylla segnis, has also been shown 
to carry the disease but does not readily parasitize humans.22  This species may pose a 
special threat, however, in that is known to cause the accumulation of significant 
amounts of fecal matter on host rats.23  This accumulation presents the possibility that a 
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limited range aerosolized version of the disease can emerge opening the possibility of 
airborne transmission.  (The theory proposed in a 1983 study suggests that, the crushed 
fecal matter could enter the air in a powdered state and be inhaled, leading to 
infection).24  Additional vectors include Ctenophthalmus congeneroides, Rhadinopsylla 
insolita, and Neopsylla bidentatiformis, which have been associated primarily with 
various species of mice.25  
Murine typhus is a relatively ubiquitous and certainly overlooked condition.  
Estimates exist that suggest between one in three and one in eight persons with the 
disease will present themselves for medical assistance.  This is likely due to the 
relatively mild symptoms many patients experience.  A fever and headache are 
symptomatic of many conditions that are commonly ignored by the populace every 
day.  The disease is interesting in that it is further complicated by the frequency 
with which patients experience “relapses” – periods of seeming recovery followed 
by a return of difficult symptoms.26 While this phenomenon may be linked to the 
drug prescribed for treatment, patients without any treatment used can still 
experience a relapse.  Seroprevalence surveys have found antibodies to Rickettsia 
typhi in significant fractions on every continent and in many countries as well, and 
cases have been reported clinically in these same locations.27-32   A map from a 
study conducted in the 1990s was located, with a list of nations with positive 
seroprevalence studies, indigenous cases, or cases from travelers.33  This map 
becomes more impressive when the implications are considered for the populace in 
these nations. The countries that reported Murine typhus contained an approximate 
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population of 5.1 billion.33  A similar map (Figure 2.1) was generated (using 
ArcMap 10.2 ESRI Redlands, California) with information from the cases 
abstracted in the study as previously described.  Areas indicated in grey were added 
from the previous source, and areas in black were new areas with Murine typhus 
(defined as a seroprevalence study, case report, outbreak, or case report of a 
traveler).  The newly added nations add approximately 970 million persons, 
bringing the total world population living in nations with Murine typhus reports to 
more than 6 billion.        
 
Figure 2.1: Murine typhus Worldwide 
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The disease itself presents in a troublingly inconsistent manner.  Common 
symptoms, once referred to as the classic triad of Murine typhus, are present in 49% of 
patients.34  The classic triad has been identified as a fever, headache, and rash, but these 
symptoms are not very useful in discriminating between diseases as they are associated 
with multiple conditions.34  Additionally, the frequency with which these symptoms 
occur seems to be subject to a great deal of variance.  Two relatively large studies in 
Greece and Cyprus, which have a relatively small geographic distance between them, 
revealed that 71% and 29% of patients showed a rash, respectively.35,36  This sort of wild 
variance in presentation is indicative of Murine typhus, and it is very rare that any two of 
the limited large studies indicate the same proportion of patients with identical 
symptoms.  This variance makes the diagnosis of the disease very difficult, and it is a 
well-known fact that earlier diagnoses allow the selection of desirable treatments more 
quickly which in turn makes treatment easier and can reduce  debilitating symptoms.37  
Murine typhus shares certain symptoms (to include the presence of high fever for a long 
period of time) with Kawasaki syndrome, a fact which can further complicate diagnoses; 
however, a recent study found no association between Murine typhus and Kawasaki 
syndrome.38,39  Certain other relatively minor symptoms to include myalgia, arthraglia, 
chills, nausea, among others also occur relatively frequently.  The worst Murine typhus 
symptoms can be very debilitating indeed, with such negative outcomes as splenic 
rupture,40-42 hearing loss,43,44 cardiovascular conditions,45 localized paralysis,46 optical 
complications,47,48 kidney failures,49 pulmonary embolism,50 intestinal difficulties to 
include obstruction,51 liver complications,52,53 and death.30,54  There are reports of 
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Murine typhus in persons of virtually every age, both genders, and a myriad of 
racial/ethnic identities.  Little information has been presented regarding socioeconomic 
status - while many cases are found in relatively poor regions, many instances of the 
disease are found in world travelers, a presumably wealthy population subset.  While the 
disease is rare enough that little information on prior medical history of concern is 
available, several case reports exist of Murine typhus in pregnant women, and the 
association between the disease and pregnancy outcomes needs exploring.55-57   
Murine typhus diagnosis is a matter of some debate as well.  While it is widely 
accepted that a quicker diagnosis leads to a better progression from symptomatic to 
asymptomatic, making this diagnosis is quite difficult.  A review of Murine typhus cases 
in Texas in the 1980s reported 20 diagnoses (not counting minute differences such as 
different forms of neoplasms and the reported “no diagnosis”) in 80 patients with 
confirmed cases (a ratio of .25 diagnoses per case).58  In modern case reports, diagnosis 
is often made on the basis of presenting symptoms confirmed by a serological report.  
The serological report of choice in recent years is the use of an IGG/IGM titer, a method 
that analyses antibody prevalence.  The titer is exposed to Murine typhus antigen and 
then analyzed again.  A four-fold increase in titer response is usually accepted as proof 
of the disease when taken along with expected symptoms, but there is some concern 
regarding the cross reactivity of the IFA titration system (most notably with Rickettsia 
prowazekii, epidemic typhus, and Rocky mountain spotted fever). Unfortunately, 
because this method takes more than a week to perform, it is rarely of use at the time an 
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initial diagnosis is needed, and is more frequently used to confirm presumptive 
diagnoses.     
Several treatment options exist for Murine typhus.  Choices of treatment can be 
debated, but the most common, and a widely accepted choice of treatment, is 
Doxycycline.  Doxycycline is a member of the tetracycline antibiotic family, and is also 
frequently prescribed as a malaria prophylactic and as a treatment for acne and facial 
blemishes.  Other treatments used have included Chloramphenicol,26 Moxifloxacin,59 
Ciprofloxacin,60 and the (relatively new) macrolide family of drugs.61  The argument has 
been made that cases with rickettsial disease are likely to experience relapses when 
treated with non-tetracycline drugs; specifically Chloramphenicol.26 More information 
on treatment choices is presented in the following chapter.     
Finally, some mention of time in hospital and the associated costs needs to be 
made here.  Of the Murine typhus cases analyzed in this study, it was found that the 
mean time (after outliers of more than 1 standard deviation were excluded) from 
admission to discharge was 10.82 days.  This compares to a US national average of 4.8 
days for all inpatients.62 While there are innumerable factors that could be considered in 
determining the cost of this increased inpatient time, a very conservative estimate 
suggests that the financial costs of a day of inpatient stay in the United States averages 
around $2,100.63  This means that an average of $12,600 in excess of the average cost of 
a hospital stay is incurred by the patient with Murine typhus.  The aforementioned lack 
of surveillance prevents me from being able to make a yearly estimate of the annual 
financial burden of Murine typhus, but it is certainly well into the millions of dollars in 
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Texas alone.  These costs do not include the loss of productivity incurred by the period 
of debilitation, the loss to quality of life for the sick individual and the community, or 
any of the special costs associated with an infectious disease.  Given that a Murine 
typhus patient usually undergoes a comprehensive battery of tests during the diagnostic 
process, it is virtually certain that the costs of Murine typhus are higher than the average 
quoted above.  A simplistic analysis might find that that time is largely due to the slow 
process of making a Murine typhus diagnosis – the mean time to recovery for the cases 
reviewed in this study once treatment begins is approximately 3.7 days when utilizing a 
tetracycline regimen.  This could be interpreted to mean that 7.2 days are attributable to 
the inability to quickly decide which drug is necessary, which in turn stems from the 
previously mentioned diagnostic difficulties, in which case $14,700 could be attributed 
per case of Murine typhus to the inability to provide expeditious diagnoses.  When 
combined with the significant morbidity and previously described suffering experienced 
by both the individual and their community, it becomes obvious that improving 
diagnostic capabilities should be a priority for public health in regard to Murine typhus.            
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CHAPTER III 
A COMPARISON OF DRUG TREATMENT METHODOLOGIES 
FOR MURINE TYPHUS 
 
 There is a great degree of variability involved in the progression of Murine 
typhus.  Patients develop symptoms, are diagnosed, treated, and respond differently than 
others with similar determinants.  While making a proper Murine typhus diagnosis has 
been demonstrated to be difficult, deciding on a treatment regimen afterward may be 
equally difficult.  There are several possible treatments for Murine typhus, and the 
debate as to the best treatment still rages in some corners.26,59,60,64   
 When assessing drug treatments, it is perhaps best to begin by considering the 
biological processes of the drugs themselves.  The most popular drug family for 
treatment of Murine typhus is undoubtedly tetracyclines.  The members of the 
tetracycline family that pertain to Murine typhus include Doxycycline (also known as 
vibramycin), the presumptive “gold standard” of Murine typhus treatment, Tigecycline, 
and Minocycline.  This family has been in use for many years and efficacy data for these 
drugs, at least when used to treat Murine typhus, is readily available (studies have 
indicated significantly reduced risk of negative outcomes for each day earlier 
Doxycycline treatment is begun in patients with rickettsial disease).65  Only one case of 
Murine typhus relapse occurred when tetracycline treatment was used.  The family is 
also commonly used for such various treatments as acne, certain types of sexually 
transmitted diseases, and as a prophylaxis for malaria prevention.66-68  Potential side 
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effects include rash, nausea, vomiting, and may cause teeth discoloration and bone 
growth inhibition in children.69  One article of those generated in the review described in 
previous chapters documented possible resistance to the effects of Doxycycline against 
Murine typhus.70   
 While the tetracyclines are a well-known family for treatment of rickettsial 
disease, another almost equally well known family is the Amphenicol family.  
Chloramphenicol carries the standard for this family when it comes to Murine typhus as 
it has been a treatment used for the disease since its introduction in the 1940s.71  It was 
noted in this early introductory study that “no highly satisfactory chemotherapeutic agent 
existed for the treatment of the rickettsial disease of man.”71  This same study also noted 
that, when studying cases of typhoid fever, (caused by Rickettsia prowazekii, a close 
relative of Rickettsia typhi) relapses of the disease occurred in two of ten patients 
tested.71  This result was mimicked in the performance of Chloramphenicol recently in a 
study of the drug’s efficacy against Murine typhus and Mediterranean spotted fever.26  
Chloramphenicol is also used against salmonellosis and certain streptococcus infections, 
although many organisms have emerged with resistance to the drug.72,73  The drug has 
many side effects, although they are rarely of a severe nature and include diarrhea, 
headaches, and inflammation at various body sites.74 
The quinolones are yet another family with some evidence of successful 
treatment for rickettsial disease.  Moxifloxacin and Ciprofloxacin (members of this 
family) both have been used against Murine typhus, although opinions and results are 
varied.59,60,64  The quinolone family (Moxifloxacin and Ciprofloxacin in particular) have 
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been used against Escherichia coli, Klebsiella pneuomoniae, Salmonella, and other 
organisms.75,76 The risk of disease relapse when used against Murine typhus is 
negligible.  Resistance has emerged against this family (and against these drugs in 
particular) in many organisms, and the minimum inhibitory concentrations of these 
drugs needed to prevent certain infections as well as the prevalence of any sort of 
resistance among organisms has increased rapidly in the past two decades among varied 
organisms and in several geographic locations.77,78  Side effects to these drugs are 
usually rare but potentially extremely severe; neurologic complications can occur and in 
2013, the FDA ordered that a warning of “possible permanent nerve damage” be placed 
on fluoroquinolones to include Ciprofloxacin and Moxifloxacin.79,80   
 Finally, the macrolides are another family of drug that has some effects against 
rickettsial disease in particular and against Murine typhus in specific.61  This family 
includes Erythromycin, Azithromycin, and Clarithromycin, as well as others, although 
the first two were the only members of the macrolide family used in the review 
conducted as previously described.  All cases of Murine typhus in pregnancy located in 
this review described previously were treated with a drug from this family (usually 
Erythromycin although one case was treated with Azithromycin).55-57   These also 
encompassed all final treatments solely with macrolide drugs as the drugs were often 
used for initial treatment although later discarded.  This class of drugs has seen relapses 
when used against Murine typhus, but this is rare (one example in the articles abstracted 
in the previously described review).  Outside of Murine typhus, macrolides are also used 
to treat a variety of diseases including various skin disorders and sometimes asthma.81,82  
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Resistance to macrolides has been observed, especially in Europe and Asia.83,84 
Gastrointestinal disturbances and rare cases of “transient” deafness are observed side 
effects, although the possibility for hepatic conditions exists.85   
 Using data from studies involved in the review conducted previously, the 
following Forest plot graphics were created using STATA 13.1 (STATACORP, College 
Station, Texas).  The average time to recovery (defined as either defervescence, report of 
relief of symptoms, or release from hospital) for each drug type is reported in Table 3.1.  
Only single-use drugs were included and any treatments involving combinations of 
drugs were excluded.    
 
 
Table 3.1: Treatments for Murine typhus by Mean Time to Recovery 
Drug name or class Uses Mean time to 
recovery 
Tetracyclines 37 4.45 
Macrolides 3 5.5 
Amphenicol 4 2 
Quionolones 5 3.1 
Overall weighted 
average of individual 
drugs in time to 
defervescence 
49 4.18 
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  A graphical representation of the times mentioned above is shown in Figure 3.1.  
A value of three is supplied as this was the previous average time to defervescence found 
in a large study of Murine typhus utilizing only the tetracycline and amphenicol 
families.58 
 
 
Figure 3.1: Graphical Representation of Recovery Time by Drug Used 
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I did not have enough cases to properly analyze any drug and would hesitate 
before making a recommendation for any of them on the basis of the data harvested in 
the systematic review described previously.  In lieu of unwarranted analysis, a table 
containing the (subjective) properties of Murine typhus treatments is included in Table 
3.2 
 
Table 3.2: A Brief Subjective Description of Treatment Options for Murine typhus 
Drug name 
or class 
Time to 
recovery 
Side effect 
severity 
Side effect 
frequency 
Resistant 
organisms 
Relapse 
frequency 
Tetracyclines Moderate Severe in 
children and 
pregnancies,  
Common in 
children and 
pregnancies,  
Rare Rare 
Macrolides Longest Mild  Common Common Rare 
Amphenicol Shortest Mild Common Common Very 
Common 
Quionolones Moderate Extreme Rare Common Unknown 
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 A further analysis of tetracycline was conducted, as it is the drug of choice for 
Murine typhus treatment in the United States.  Tetracycline cases with no listed time to 
recovery were excluded from this analysis.  The value 4.45 days to recover, as 
mentioned in Figure 3.1, has already been reported.  This number was very dissimilar to 
the 1980s figure of three days to recovery.58  Further analysis removed the three outliers 
greater than one standard deviation from the mean and the data was reanalyzed.  These 
cases were removed and a new analysis revealed that the time to defervescence mean for 
Murine typhus with tetracyclines dropped from 4.45 days/case to 3.7 days/case.  This 
still, however, represented a 22% increase in time to treat over the previously reported 
mean of three.58 This previous study was selected as it was the largest available Murine 
typhus study with recorded treatments and contained both tetracycline and 
Chloramphenicol treatments.58  A brief examination using Student’s t-test revealed that 
this difference was classically significant with a p-value of .01.  Unfortunately, the 
sample size involved in this analysis is likely too small to be of much use in determining 
any interesting information about this trend; however, more research into why this 
apparent increase has occurred could be fruitful.   
 Murine typhus remains a difficult to diagnose and perhaps more difficult to treat 
disease, and treatment choices, once abundant, are becoming more limited as resistances 
continue to become more common to most of the treatments.  Vigilant surveillance to 
detect any emergent resistance phenomena in Murine typhus is recommended.   
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CHAPTER IV 
 MURINE TYPHUS: AN EMERGING PUBLIC HEALTH THREAT FOR 
TEXAS 
That Murine typhus is on the rise in many regions and nations is not under 
debate. Recent outbreaks have been reported in Hawaii,86 California,87 and Texas (most 
notably Austin),88 while cases described as “the first report of Murine typhus from” or 
“Murine typhus in a place it was not expected” continue to be seen.17 Texas experienced 
a thirteen times increase in Murine typhus cases from 2001-2011.89  Figure 4.1 shows a 
visualization of Murine typhus in Texas from the estimates of 1930 to the decrease in the 
late 1940s and on to present day.   The obvious decrease in the 1940s was likely due to 
the introduction of DDT as mentioned earlier and discussed further in this chapter.  
Figure 4.1:  Murine typhus Cases in Texas 
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The Texas Department of State Health Services (DSHS) mentions this increase 
as being attributable to two causes; increased surveillance on border counties (Mexico is 
an area of relatively high endemicity for the disease and there is a potential for 
movement of the disease)89,90 and migration of Murine typhus into areas where it has not 
appeared before.  Texas, like many regions in similar latitudes, offers an environment of 
sufficient warmth for the disease to flourish.19  That Murine typhus is emerging in new 
counties in the state is widely accepted.  From 2006 to 2010, the number of counties 
with clinically and serologically confirmed murine typhus reports rose from 13 to 18.90 It 
is important to note that these cases could have been acquired in different counties than 
the county of residence for the reported cases.  With this in mind, the trend reported 
should be considered, but the author hesitates to state that these specific counties are 
endemic areas for Murine typhus (a notable exception can be made for the counties on 
the border with Mexico, as this region of endemicity has been a consistent reporter of 
murine typhus in Texas).    
While the reasons for this increase are difficult to identify definitively, it is worth 
a moment to mention the decline and subsequent ban on the use of the insecticide DDT 
at this juncture.  A pre-DDT implementation paper found that after a first application of 
DDT in two counties in the United States, rats that were seroprevalent to Murine typhus 
decreased greatly when compared to those in a neighboring county that was untreated as 
well as to prior numbers.91  A decrease from a high of greater than 60% of rats sampled 
yielding a positive seroprevalence test to a high of less than 20% in one county, and a 
decrease from a high of 50% to a high of approximately 10% in the other county was 
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reported.91  The same study suggested that human Murine typhus cases reduced 
“considerably” and later “significantly,” but no analysis was presented in quantitative 
terms.91   The same paper stated that harvested numbers of Xenopsylla Cheopis (one of 
the main vectors of Murine typhus infection) did not return to the level prior to use of 
DDT within three years (unfortunately no further data was available).91    
 DDT was almost universally sprayed in the United States prior to 1972.92 Many 
other nations, both industrialized and non-industrialized, used the chemical during the 
same time period to one degree or another.  This may have resulted in a protective effect 
of sorts against the insects that harbor the disease, as DDT remains in the soil for years.93 
Even at the relatively low depth of only six inches, 30% of DDT applied can be found 15 
years later, and the Environmental Protection Agency has estimated the half-life of DDT 
in soil to be 15 years.93   It is possible that the protective effects of the insecticide have 
now dissolved to a sufficient level to allow for a rise in vectors and a subsequent rise in 
cases noted in the increased number of Murine typhus reports and surveillance data 
presented above. 
 While DDT was supremely effective, new insecticides have been developed in 
the past 50 years.  Specifically, Fipronil has been shown to be effective in several ways – 
it can be applied directly to an animal and fleas will then ignore the animal.  If this 
treatment lasts long enough (one or more years), widespread use of this chemical may 
lead to a significant reduction in eligible reservoirs for Murine typhus and a subsequent 
decrease in cases of the disease.94 Several other non-chemical methods to prevent 
Murine typhus exist as well.  Campaigns to promote public awareness about fleas, the 
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warning signs/how to identify flea bites, and how to prevent animals from coming into 
contact with fleas may also be of use.  Finally, most major cities have rodent control 
programs.  Improved rodent surveillance and disposal methods may be able to reduce the 
burden of Murine typhus in and of itself.  
 An increase in reported cases of any disease in a similar manner to that found in 
Murine typhus in Texas would be cause for concern.  When considered with regard to 
the relatively unique difficulties that are accompanied by Murine typhus, this increase 
could represent a grave threat indeed.  One of the major difficulties with Murine typhus 
is obtaining a proper diagnosis.  An analysis of 80 patients in South Texas found that 
there were 20 unique diagnoses (not including “no diagnosis” and proposed differential 
causes of neoplasms).58  Murine typhus represented 11% of the diagnoses made.58  The 
analysis in this document showed an even lower number – only 5.8% of diagnoses were 
correct.  Diagnostic ability has not increased since 1980 either.  While Texas represented 
approximately 10% of the cases in phase 2 analysis presented earlier in Table 1.3, not a 
single case diagnosed properly on first attempt was located in Texas.  Diagnostic 
efficiency increases are important due to the fact that early treatment with Doxycycline 
(not a commonly used antibiotic without suspicion of rickettsial illness) decreases risk of 
certain severe complications in rickettsial disease (to include death) by 20%.65 Reasons 
for the difficulty of diagnosis are difficult to come by, but many answers have been 
theorized to include the relative ubiquity of common symptoms (fever, headache, and 
rash are not unique to Murine typhus), the long time delay required for appropriate 
analysis of a seroprevalence test (seroprevalence assays have been shown to have 
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confirmed 100% of Murine typhus diagnoses in a South Texas study within 15 days after 
presentation of symptoms), and the lack of attention granted to tropical diseases in 
general.92   
 While an increasing total number of Murine typhus cases is undoubtedly a 
worrying trend, a change in the geographical prevalence of Murine typhus cases merely 
compounds this concern.  One additional potential difficulty concerns the treatments 
used for Murine typhus themselves.  While Doxycycline has been accepted as the drug 
of choice for Murine typhus in recent years, there are problems associated with this drug.  
Doxycycline (along with many other tetracyclines, which are also efficacious against 
Murine typhus) has experienced shortages in recent years.95   With an increasing number 
of Murine typhus cases, this could lead to a shortage at a time of great potential need.  
Doxycycline is contraindicated for use for pregnant women, who may or may not be at 
greater risk for Murine typhus acquisition, but are definitely a population with specific 
health concerns of interest to public health planners.  Further, if supported by future 
research, the trend of decreased Doxycycline efficacy presented previously could also 
add to the list of problems Murine typhus poses for Texas.      
 Texas is a state blessed with many resources.  However, the presence of a long 
border with an area of relatively high endemicity, an environment desirous to both 
vectors and reservoirs of Murine typhus, and the existence of the aforementioned trends 
and problems in Murine typhus management mean that the potential for a public health 
problem caused by Murine typhus is relatively high.  Fortunately, all of the problems 
that the state faces (outside of the favorable environment and geography for Murine 
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typhus) can be addressed.  An improvement in diagnostic ability does not seem 
impossible – an increased presence of rickettsial disease knowledge can help address 
some of the diagnostic problems immediately simply by raising awareness.  A 2006 
study found that a lack of knowledge was the third leading cause of certain missed 
diagnoses, and the diagnoses in question were primarily those much more common 
(cancer, heart disease, etc) than the currently rare Murine typhus.96  While no small 
undertaking, improving knowledge in any population can be done in a relatively 
expeditious manner.  The potential to incorporate Bayesian statistics, a set of methods 
well known for defining causality in the process safety world, may be useful to help 
improve diagnostic abilities.  Additionally, as more studies are conducted regarding the 
organism, the amount of information available will continue to rise and new 
understandings of the way the disease presents itself and is diagnosed will likely follow.  
New pesticides to replace DDT have been developed and have been used in many areas.  
Drug shortages can be managed and alleviated with increased production or possibly 
simply better management of resources.  Other drugs have been shown to be effective 
against Murine typhus – Chloramphenicol, Ciprofloxacin, and Moxifloxacin all have 
promise for use as treatments for Murine typhus, although at least some drawbacks 
exist.26,37,59  
 Murine typhus has the potential to pose a major threat to the state of Texas in the 
coming years.  This threat may also “pass in the night” and never manifest as more than 
a few hundred cases a year.  Regardless, continued research into Murine typhus, in 
conjunction with proper public health planning and surveillance, is important to maintain 
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the level of knowledge and readiness we now possess and to improve upon these 
qualities to reduce the potential for Murine typhus to present a public health threat to 
Texas.     
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CHAPTER V 
CONCLUSIONS   
 
 The difficulties that Murine typhus poses for Texas, and for the world as a whole, 
cannot be understated.  An increasing incidence, combined with the spread of the disease 
to new geographic regions means that there will be few nations not affected by the 
disease in the coming years.  Difficulties with surveillance and pest control will continue 
to be a problem as well, as a pesticide with similar efficacy to DDT does not exist.  If 
future research, both epidemiologic and on a microbial/biochemical basis substantiates 
the aforementioned observations with regard to decreasing treatment efficacy, another 
problem will have emerged.  Additionally, the lack of ability to procure quick and 
accurate diagnoses of cases of Murine typhus will only exacerbate these other problems.   
 However, one advantage of a public health problem is the impetus that it gives to 
research.  With Murine typhus, research is not so much a matter of “filling in the gaps” 
as it is establishing a base structure.  One article reviewed eloquently described Murine 
typhus as “forgotten, but not gone.”97  This is an excellent summary of the situation with 
regard to Murine typhus.  Many of the studies cited here were conducted in the 1940s.  
There is a great deal of room for innovation with regard to Murine typhus and the 
problems it poses, and many new studies will be needed to address these problems.  
Specifically, a large scale statistical study of Murine typhus treatments could 
substantiate the trends found in the section on drug use in Murine typhus.  Additionally, 
an analysis of the minimum inhibitory concentrations of various drugs on Murine typhus 
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is likely to reveal some changes in the organism.   The rise in tools of molecular 
epidemiology is encouraging, as inferences from these tools have allowed the tracing of 
strains of disease responsible for specific trends, and these tools could also be applied to 
help make similar determinations about Murine typhus.   
 Epidemiologically, analyses of certain populations (the young, elderly, groups of 
varying socioeconomic status and race, and especially pregnant women) are likely to be 
exceptionally fruitful.  While this author chose not to formally present any findings 
concerning pregnant women, it is very likely that they are disproportionately affected by 
Murine typhus on the basis of their over-representation in the articles reviewed in this 
study.  Research into prevalence of the disease and outcomes in pregnant women could 
be very productive.   
 Finally, a word should be spoken about the potential that Bayesian statistics 
holds with regard to further research into this organism.  The prevalence of this 
methodology in the world of process analysis, combined with unique problems posed by 
Murine typhus, makes this the most likely way to address the aforementioned problems 
with diagnostics.  The author attempted to form such an analysis of predictors of hospital 
stay length as a crude predecessor to a more properly designed Bayesian analysis of 
factors that influence hospital stay length.  While the small sample size yielded an overly 
specific analysis that was of little use, these statistics remain likely the best way to 
analyze and improve the weaknesses found in identifying Murine typhus cases (barring a 
rapid analysis for the disease).   
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 Murine typhus represents an emerging public health threat, but the world 
scholastic community is well equipped to meet this challenge.  All that needs to be done 
is a bit of redirection of effort and the threat posed by Murine typhus can again be 
reduced until the disease is truly “gone, but not forgotten.”     
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